Canada Latent Tuberculosis Infection Detection Market Size, Report 2022 to 2030

The Canada latent tuberculosis infection detection market size was recorded at USD 27.4 million in 2021 and it is expected to surpass around USD 47.31 million by 2030, poised to grow at a CAGR of 6.26% from 2022 to 2030.

Canada Latent Tuberculosis Infection Detection Market Size 2021 to 2030

The rising infection rate of latent TB in the indigenous population and high inbound traveling from the regions where TB is endemic are the major factors increasing the demand for latent tuberculosis infection screening. Moreover, the surge in tuberculosis testing and ongoing research activities to develop novel TB tests is another factor contributing to market expansion.

Immediate Delivery Available | Get the sample copy of report@ https://www.visionresearchreports.com/report/sample/39758

The increasing incidence of latent tuberculosis infection in the country is expected to fuel the demand for testing. Most people infected with M. tuberculosis remain asymptomatic, however, about 5% of latent TB infections develop into active cases. The goal of public health authorities to test for LTBI and to identify people at high risk of developing TB disease is increasing the demand for tuberculosis testing.

According to data published by the Canadian Medical Association, around 70% of immigrants to Canada come from Asia, Africa, and Latin American countries where TB infection is endemic. Out of these immigrants, around 50% are estimated to have latent tuberculosis infection. Moreover, around two-thirds of reported cases occur in foreign-born individuals in Canada.

Canada’s government is taking favorable initiatives to achieve WHO’s goal to eliminate the disease in the country. It has already achieved the End TB target milestone, an action plan by the WHO to eliminate the disease by 2050. Optimal management of tuberculosis and improvement in healthcare infrastructure is expected to eradicate the disease in the coming years.

Moreover, increasing recommendations for latent TB infection tests for the high-risk population in the country is expected to fuel market growth. The Canadian TB Standards recommend the use of TST and IGRA for the detection of LTBI. IGRAs are preferred to test LTBI in individuals who have taken the BCG vaccine and in groups with poor TST test results. However, TST is mainly recommended when repeated testing is planned.

The screening for LTBI of immigrants and the general population in the country is low. About 2.5% of new immigrants are flagged for surveillance after reaching the country. Medical screening programs for immigrants in Canada do not specifically include screening for LTBI and it is not mentioned in most lists of reportable diseases in the country. The inclusion of LTBI screening in surveillance programs in the country may increase the demand for latent tuberculosis tests in the coming years.

The reimbursement for tests used to detect latent tuberculosis infection is provided for people who have been identified as having contact with active cases or those at high risk of developing active TB. The reimbursement for TB testing is decentralized in the country and is provided at the province level with certain criteria. The government does not recommend latent tuberculosis infection testing and reimbursement to the general population in the country.

Most states in Canada have established three priority strategies for the prevention and management of the disease; identification of people with tuberculosis infection, investigation of contacts of infectious TB, and investigation of the population at high risk for latent TB infection. Such strategies to manage the disease in the country will increase the demand for screening tests for tuberculosis infections.

Scope of The Report

Report Coverage

Details

Market Size in 2021

USD 27.4 million
 

Revenue Forecast by 2030

USD 47.31 million

Growth rate from 2022 to 2030

CAGR of 6.26%
 

Base Year

2021

Forecast Period

2022 to 2030

Segmentation

Test type, end-use, province
 

Companies Covered

F. Hoffmann-La Roche Ltd, Abbott, QIAGEN, BD (Becton, Dickinson, and Company), bioMérieux SA., Oxford Immunotec USA, Inc.

 

Test Type Insights

Based on test type, the interferon-gamma release assay segment was the major revenue generator in 2021. Increasing awareness about TB infection and increasing recommendations for IGRAs from various public health authorities has boosted its adoption for LTBI detection. Health Canada has approved two IGRAs tests; QuantiFERON-TB Gold (QFT-GIT) assay by Qiagen and T-SPOT.TB assay by Oxford Immunotec for the detection of latent TB infections.

The IGRA segment is anticipated to experience the fastest growth over the forecast period. High test sensitivity and increasing adoption of IGRAs due to their advantages over TSTs are some of the key factors driving the segment growth over the forecast period.

However, the tuberculin skin test segment dominated in terms of the number of tests performed for the detection of LTBI. High market penetration and cost-effectiveness of the test have boosted the adoption of tests in the country. In Canada, Tubersol 5 tuberculin units of purified protein derivative are recommended to conduct a tuberculin skin test. Sanofi is one of the major players providing tuberculin-purified protein derivatives in Canada.

Immediate Delivery Available | Buy this Premium Research Report@ https://www.visionresearchreports.com/report/cart/39758

End-use Insights

The diagnostic laboratories segment dominated the Canada latent tuberculosis infection detection market owing to efforts to improve patient outcomes by providing precise & prompt reporting at the retail level. Moreover, the ability of laboratories to handle a large volume of tests at an expedited rate is expected to further fuel the segment over the forecast period. Diagnostics laboratories such as Dynacare and Life Labs provide blood tests for the detection of latent TB infection in the country.

The hospital & clinics segment held the second-largest market share in 2021 owing to the high risk of getting tuberculosis infections in healthcare facilities. Moreover, individuals with medical conditions, such as HIV/AIDS, chronic renal failure, and other diseases that weaken the immune system, increase the risk of LTBI and its development into an active TB case. However, the academic & research institutions segment is expected to experience the fastest growth rate over the forecast period.

Regional Insights

Canada’s latent tuberculosis infection detection industry is classified into provinces and territories. Ontario province led the market and it is expected to maintain its dominance over the forecast period. The large market share of the province can be attributed to its large population base, high immigration rate compared to other provinces, and better healthcare infrastructure. The immigration rate is highest in Ontario; it welcomes around 40% of the total immigrants of Canada every year. Similarly, British Columbia, Quebec, Alberta, and Manitoba also held a significant share of the LTBI detection market.

North Canada region including Yukon, Northwest Territories, and Nunavut is expected to grow at a faster growth rate compared with other parts of Canada. Improvement of healthcare facilities, a high portion of the indigenous population, and other factors increasing the risk of developing tuberculosis disease are driving the growth of the market in these regions.

Key Players

  • Abbott
  • QIAGEN
  • F. Hoffmann-La Roche Ltd
  • Sanofi
  • Oxford Immunotec USA
  • ARKRAY, Inc.
  • bioMérieux SA

Market Segmentation

  • By Test Type Outlook
    • Tuberculin Skin Test
    • Interferon Gamma Release Assays
  • By End-use Outlook
    • Diagnostic Laboratories
    • Hospitals/Clinics
    • Academic & Research Institutions
  • By Province Outlook
    • Alberta
    • British Columbia
    • Manitoba
    • New Brunswick
    • Nova Scotia
    • Ontario
    • Prince Edward Island
    • Quebec
    • Saskatchewan
    • Northwest Territories
    • Nunavut
    • Yukon
    • Newfoundland & Labrador   

Click Here to View Full Report Table of Contents

Immediate Delivery Available | Buy this Premium Research Report@ https://www.visionresearchreports.com/report/cart/39758

You can place an order or ask any questions, please feel free to contact at sales@visionresearchreports.com | +1 9197 992 333

Blog: https://www.novaoneadvisor.com/

Blog: https://qyresearchmedical.com/

Back to news